Pranay Dey - Publications

2017- Molecular Functional Imaging Lab ACTREC- Tata Memorial Centre 

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Goel S, Dey P, Dahiya D, Bhatia A. A not so worthless attempt to develop primary culture from breast FNAC/CNB samples! Tissue & Cell. 71: 101517. PMID 33677200 DOI: 10.1016/j.tice.2021.101517  0.464
2021 Dey P, Kimmelman AC, DePinho RA. Metabolic Codependencies in the Tumor Microenvironment. Cancer Discovery. PMID 33504580 DOI: 10.1158/2159-8290.CD-20-1211  0.339
2020 Mal A, Dey P, Hayes RM, McCarthy JV, Ray A, De A. Identification of Potential Phosphorylation in the Cytoplasmic Domain of Epithelial Cell Adhesion Molecule. Acs Omega. 5: 30808-30816. PMID 33324790 DOI: 10.1021/acsomega.0c02113  0.653
2020 Yan S, Dey P, Ziegler Y, Jiao X, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer. Breast Cancer Research and Treatment. PMID 33001337 DOI: 10.1007/s10549-020-05948-0  0.506
2020 Dey P, Wang A, Ziegler Y, Kim SH, El-Ashry D, Katzenellenbogen JA, Katzenellenbogen BS. Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer. Cancers. 12. PMID 32961773 DOI: 10.3390/Cancers12092677  0.536
2020 Dey P, Kundu A, Han SH, Kim KS, Park JH, Yoon S, Kim IS, Kim HS. Biological Evaluation of Oxindole Derivative as a Novel Anticancer Agent against Human Kidney Carcinoma Cells. Biomolecules. 10. PMID 32878322 DOI: 10.3390/biom10091260  0.339
2020 Pack CD, Bommireddy R, Munoz LE, Patel JM, Bozeman EN, Dey P, Radhakrishnan V, Vartabedian VF, Venkat K, Ramachandiran S, Reddy SJC, Selvaraj P. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Human Vaccines & Immunotherapeutics. 1-10. PMID 32530786 DOI: 10.1080/21645515.2020.1754691  0.329
2019 Dey P, Rathod M, De A. Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Medical Press). 11: 115-135. PMID 30881110 DOI: 10.2147/BCTT.S189224  0.728
Show low-probability matches.